Previous 10 |
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a late-breaking poster presentation for its AUTO1 program at the American Association o...
Autolus Therapeutics plc (AUTL) Transition Period from October 1 to December 31, 2018 February 25, 2019 8:00 am ET Corporate Participants Silvia Taylor - Vice President, Corporate Affairs and Communications Christian Itin - Chairman and Chief Executive Officer Andrew Oakley - Chi...
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Vineti Inc, the leading software platform of record for personalized therapeutics, today announced a new partnership to help advance and scale Autolus Therapeutics plc (NASDAQ: AUTL)’s broad clinical stage pipeline of cancer treatments...
Autolus Therapeutics (NASDAQ: AUTL ): GAAP EPS of -$0.52 beats by $2.51. More news on: Autolus Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
LONDON , Feb. 25, 2019 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the transition period from October 1 to D...
LONDON , Feb. 21, 2019 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the company will release its operating and ...
Updated data from a Phase 1 clinical trial, CARPALL , evaluating Autolus Therapeutics' ( AUTL -1.4% ) CD19 CAR T candidate AUTO1 in heavily pretreated pediatric patients with acute lymphoblastic leukemia (ALL) showed a positive effect with a favorable safety profile. The results were p...
LONDON , February 19, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL), has presented updated data from the ongoing Phase 1...
LONDON , Feb. 19, 2019 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that Professor Persis Amrolia, Consultant in Bone Mar...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...